Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Adverum Biotechnologies (ADVM) reported a Q3 loss of $1.30 per share, which was larger than the Zacks Consensus Estimate of a $1.20 loss. However, this is an improvement from the $3.30 loss per share reported a year ago.
November 05, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Adverum Biotechnologies reported a Q3 loss of $1.30 per share, missing the Zacks Consensus Estimate of a $1.20 loss. Despite missing estimates, the loss is an improvement from the previous year's $3.30 per share.
The reported loss per share was worse than expected, which is typically negative for stock prices. However, the improvement from the previous year's loss may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100